> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Stakeholders Comment on Rhinosinusitis Draft
- URL: https://www.fdaweb.com/stakeholders-comment-on-rhinosinusitis-draft/
- Published: 2022-02-09T12:00:00.000Z
- Updated: 2026-09-14T17:31:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151125

AstraZeneca says a need remains to develop additional medical products with alternate methods of action to address the burden of chronic sinusitis with nasal polyps. The company [commented](https://downloads.regulations.gov/FDA-2021-D-1096-0006/attachment%5F1.pdf?ref=fdaweb.com) in response to an FDA draft guidance, *Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment*. It says the draft “serves as a valuable resource to assist medical product developers in their efforts to develop new drugs for this condition.” AstraZeneca provides several specific comments.

GlaxoSmithKline [provided](https://downloads.regulations.gov/FDA-2021-D-1096-0004/attachment%5F1.pdf?ref=fdaweb.com) general and specific comments with proposed modifications where appropriate.

Regeneron also supplied specific [comments](https://downloads.regulations.gov/FDA-2021-D-1096-0005/attachment%5F1.docx?ref=fdaweb.com).